You just read:

Once-Daily, Oral SAVAYSA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

News provided by

Daiichi Sankyo, Inc.

Dec 12, 2017, 07:31 ET